$2.21
-0.05 (-2.21%)
Open$2.26
Previous Close$2.26
Day High$2.29
Day Low$2.20
52W High$3.22
52W Low$1.80
Volume—
Avg Volume2.75M
Market Cap132.02M
P/E Ratio8.67
EPS$0.17
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,318.1% upside
Current
$2.21
$2.21
Target
$31.34
$31.34
$21.51
$31.34 avg
$48.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 71.13M | 66.06M | 30.93M |
| Net Income | 9.13M | 7.63M | -5,880,957 |
| Profit Margin | 12.8% | 12.2% | -19.0% |
| EBITDA | 6.72M | 5.93M | -8,827,347 |
| Free Cash Flow | — | — | -6,633,459 |
| Rev Growth | +7.7% | +7.7% | +18.4% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |